Found: 74
Select item for more details and to access through your institution.
A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder.
- Published in:
- Human Psychopharmacology: Clinical & Experimental, 2009, v. 24, n. 2, p. 145, doi. 10.1002/hup.999
- By:
- Publication type:
- Article
In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes.
- Published in:
- Human Psychopharmacology: Clinical & Experimental, 2001, v. 16, n. 7, p. 541, doi. 10.1002/hup.328
- By:
- Publication type:
- Article
Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1332394
- By:
- Publication type:
- Article
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1101, doi. 10.1111/dom.14313
- By:
- Publication type:
- Article
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2493, doi. 10.1111/dom.14175
- By:
- Publication type:
- Article
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 798, doi. 10.1111/dom.13958
- By:
- Publication type:
- Article
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2684, doi. 10.1111/dom.13858
- By:
- Publication type:
- Article
Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2667, doi. 10.1111/dom.13855
- By:
- Publication type:
- Article
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2684, doi. 10.1111/dom.13858
- By:
- Publication type:
- Article
Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2667, doi. 10.1111/dom.13855
- By:
- Publication type:
- Article
Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1381, doi. 10.1111/dom.13664
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 876, doi. 10.1111/dom.13593
- By:
- Publication type:
- Article
Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 829, doi. 10.1111/dom.13586
- By:
- Publication type:
- Article
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 2034, doi. 10.1111/dom.13326
- By:
- Publication type:
- Article
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 479, doi. 10.1111/dom.13126
- By:
- Publication type:
- Article
Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 9, p. 619, doi. 10.2165/11590290-000000000-00000
- By:
- Publication type:
- Article
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
- Published in:
- Clinical Pharmacology & Therapeutics, 2002, v. 71, n. 1, p. 30, doi. 10.1067/mcp.2002.119815
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2001, v. 70, n. 1, p. 48, doi. 10.1067/mcp.2001.116793
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1997, v. 62, n. 2, p. 138, doi. 10.1016/S0009-9236(96)90068-5
- By:
- Publication type:
- Article
Validation and application of a high-performance liquid chromatography/tandem mass spectrometry assay for sumatriptan in human plasma.
- Published in:
- Biomedical Chromatography, 2003, v. 17, n. 1, p. 48, doi. 10.1002/bmc.211
- By:
- Publication type:
- Article
958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-958-P
- By:
- Publication type:
- Article
6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-6-LB
- By:
- Publication type:
- Article
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-Daily Oral Doses of Saxagliptin for 2 Weeks in Type 2 Diabetic and Healthy Subjects.
- Published in:
- Diabetes, 2007, v. 56, p. A161
- By:
- Publication type:
- Article
Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone.
- Published in:
- Chirality, 2000, v. 12, n. 9, p. 681, doi. 10.1002/1520-636X(2000)12:9<681::AID-CHIR7>3.0.CO;2-J
- By:
- Publication type:
- Article
Fate of the Flavonoid Quercetin in Human Cell Lines: Chemical Instability and Metabolism.
- Published in:
- Journal of Pharmacy & Pharmacology, 1999, v. 51, n. 3, p. 353, doi. 10.1211/0022357991772367
- By:
- Publication type:
- Article
Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1229255
- By:
- Publication type:
- Article
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin.
- Published in:
- Advances in Therapy, 2012, v. 29, n. 2, p. 163, doi. 10.1007/s12325-011-0098-x
- By:
- Publication type:
- Article
A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons.
- Published in:
- Frontiers in Medicine, 2023, p. 1, doi. 10.3389/fmed.2023.1241456
- By:
- Publication type:
- Article
Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open‐Label Randomized Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 4, p. 549, doi. 10.1002/cpdd.634
- By:
- Publication type:
- Article
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 10, p. 1856, doi. 10.1002/ejhf.2649
- By:
- Publication type:
- Article
Population Pharmacodynamic Dose–Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 4, p. 551, doi. 10.1007/s40262-024-01360-9
- By:
- Publication type:
- Article
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 5, p. 655, doi. 10.1007/s40262-023-01238-2
- By:
- Publication type:
- Article
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 5, p. 551, doi. 10.1002/jcph.2196
- By:
- Publication type:
- Article
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 10, p. 1227, doi. 10.1002/jcph.2062
- By:
- Publication type:
- Article
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 8, p. 1018, doi. 10.1002/jcph.2043
- By:
- Publication type:
- Article
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 4, p. 541, doi. 10.1002/jcph.1987
- By:
- Publication type:
- Article
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 5, p. 636, doi. 10.1002/jcph.1769
- By:
- Publication type:
- Article
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- Published in:
- Cardiovascular Diabetology, 2019, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12933-019-0942-x
- By:
- Publication type:
- Article
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 5, p. 1122, doi. 10.1111/bcp.12425
- By:
- Publication type:
- Article
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 76, n. 3, p. 432, doi. 10.1111/bcp.12056
- By:
- Publication type:
- Article
Simultaneous oral therapeutic and intravenous <sup>14</sup>C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 75, n. 3, p. 763, doi. 10.1111/j.1365-2125.2012.04391.x
- By:
- Publication type:
- Article
The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.
- Published in:
- British Journal of Clinical Pharmacology, 2011, v. 72, n. 5, p. 775, doi. 10.1111/j.1365-2125.2011.04003.x
- By:
- Publication type:
- Article
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2011, v. 72, n. 1, p. 92, doi. 10.1111/j.1365-2125.2011.03937.x
- By:
- Publication type:
- Article
A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.
- Published in:
- British Journal of Clinical Pharmacology, 2001, v. 51, n. 4, p. 350, doi. 10.1046/j.1365-2125.2001.01360.x
- By:
- Publication type:
- Article
Letters to the Editor.
- Published in:
- 1999
- By:
- Publication type:
- Letter
Transplacental distribution of salbutamol enantiomers at Caesarian section.
- Published in:
- British Journal of Clinical Pharmacology, 1997, v. 44, n. 6, p. 587, doi. 10.1046/j.1365-2125.1997.t01-1-00617.x
- By:
- Publication type:
- Article
Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 8, p. 1924, doi. 10.1093/ckj/sfaa237
- By:
- Publication type:
- Article
Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 7, p. 1808, doi. 10.1093/ckj/sfaa222
- By:
- Publication type:
- Article
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 2, p. 606, doi. 10.1111/bcp.15939
- By:
- Publication type:
- Article